160 related articles for article (PubMed ID: 35129305)
1. The outcome of watchful waiting in patients with previously treated follicular lymphoma.
Fujino T; Maruyama D; Maeshima AM; Saito Y; Ida H; Hosoba R; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Kuroda J; Izutsu K
Cancer Med; 2022 May; 11(10):2106-2116. PubMed ID: 35129305
[TBL] [Abstract][Full Text] [Related]
2. Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era.
Yuda S; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto KI; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Tajima K; Taniguchi H; Tobinai K
Ann Hematol; 2016 Dec; 95(12):2017-2022. PubMed ID: 27666284
[TBL] [Abstract][Full Text] [Related]
3. The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma.
Davies GA; Ghosh S; Oh DH; Manna M; Peters AC; Stewart CA; Stewart DA
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):829-835. PubMed ID: 30243571
[TBL] [Abstract][Full Text] [Related]
4. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era.
Nastoupil LJ; Sinha R; Byrtek M; Ziemiecki R; Zhou X; Taylor M; Friedberg JW; Link BK; Cerhan JR; Dawson K; Flowers CR
Br J Haematol; 2016 Mar; 172(5):724-34. PubMed ID: 26729445
[TBL] [Abstract][Full Text] [Related]
5. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database.
Solal-Céligny P; Bellei M; Marcheselli L; Pesce EA; Pileri S; McLaughlin P; Luminari S; Pro B; Montoto S; Ferreri AJ; Deconinck E; Milpied N; Gordon LI; Federico M
J Clin Oncol; 2012 Nov; 30(31):3848-53. PubMed ID: 23008294
[TBL] [Abstract][Full Text] [Related]
6. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369
[TBL] [Abstract][Full Text] [Related]
7. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
[TBL] [Abstract][Full Text] [Related]
8. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
Prica A; Chan K; Cheung M
Cancer; 2015 Aug; 121(15):2637-45. PubMed ID: 25877511
[TBL] [Abstract][Full Text] [Related]
9. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
[TBL] [Abstract][Full Text] [Related]
10. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
Peñalver FJ; Márquez JA; Durán S; Giraldo P; Martín A; Montalbán C; Sancho JM; Ramírez MJ; Terol MJ; Capote FJ; Gutiérrez A; Sánchez B; López A; Salar A; Rodríguez-Caravaca G; Canales M; Caballero MD;
Cancer Med; 2019 Nov; 8(16):6955-6966. PubMed ID: 31573746
[TBL] [Abstract][Full Text] [Related]
11. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.
Casulo C; Day B; Dawson KL; Zhou X; Flowers CR; Farber CM; Hainsworth JD; Cerhan JR; Link BK; Zelenetz AD; Friedberg JW
Ann Oncol; 2015 Nov; 26(11):2311-7. PubMed ID: 26362568
[TBL] [Abstract][Full Text] [Related]
12. [Low grade lymphoma: research progress and questions about treatment].
Ishizawa K
Rinsho Ketsueki; 2015 Oct; 56(10):2039-46. PubMed ID: 26458443
[TBL] [Abstract][Full Text] [Related]
13. Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG.
Binkley MS; Brady JL; Hajj C; Chelius M; Chau K; Balogh A; Levis M; Filippi AR; Jones M; Ahmed S; MacManus M; Wirth A; Oguchi M; Vistisen AK; Andraos TY; Ng AK; Aleman BMP; Choi SH; Kirova YM; Hardy S; Reinartz G; Eich HT; Bratman SV; Constine LS; Suh CO; Dabaja B; El-Galaly TC; Hodgson DC; Ricardi U; Yahalom J; Mikhaeel NG; Hoppe RT
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):522-529. PubMed ID: 30858143
[TBL] [Abstract][Full Text] [Related]
14. Phase III study of watchful waiting vs. rituximab as first-line treatment in advanced stage follicular lymphoma with low tumour burden (JCOG1411, FLORA study).
Miyamoto K; Fukuhara N; Maruyama D; Shibata T; Nakamura K; Ishizawa K; Tsukasaki K; Nagai H;
Jpn J Clin Oncol; 2018 Aug; 48(8):777-780. PubMed ID: 29901705
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years.
Barzenje DA; Cvancarova Småstuen M; Liestøl K; Fosså A; Delabie J; Kolstad A; Holte H
PLoS One; 2015; 10(7):e0131158. PubMed ID: 26147646
[TBL] [Abstract][Full Text] [Related]
16. [Treatment strategies for follicular lymphoma].
Fukuhara N
Rinsho Ketsueki; 2023; 64(9):1019-1025. PubMed ID: 37899178
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological factors and tumor microenvironment markers predicting watch-and-wait discontinuation in 82 patients with follicular lymphoma.
Yuda S; Miyagi Maeshima A; Taniguchi H; Ito Y; Hatta S; Suzuki T; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
Eur J Haematol; 2021 Jul; 107(1):157-165. PubMed ID: 33905571
[TBL] [Abstract][Full Text] [Related]
18. Predicting time to treatment in follicular lymphoma on watchful waiting using baseline metabolic tumour burden.
Leccisotti L; Maccora D; Malafronte R; D'Alò F; Maiolo E; Annunziata S; Rufini V; Giordano A; Hohaus S
J Cancer Res Clin Oncol; 2023 Jul; 149(7):2783-2791. PubMed ID: 35779106
[TBL] [Abstract][Full Text] [Related]
19. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance.
Tobin JWD; Rule G; Colvin K; Calvente L; Hodgson D; Bell S; Dunduru C; Gallo J; Tsang ES; Tan X; Wong J; Pearce J; Campbell R; Tneh S; Shorten S; Ng M; Cochrane T; Tam CS; Abro E; Hawkes E; Hodges G; Kansara R; Talaulikar D; Gilbertson M; Johnston AM; Savage KJ; Villa D; Morris K; Ratnasingam S; Janowski W; Kridel R; Cheah CY; MacManus M; Matigian N; Mollee P; Gandhi MK; Hapgood G
Blood Adv; 2019 Oct; 3(19):2804-2811. PubMed ID: 31570492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
